Mouse cells productively infected with Moloney murine leukemia virus were treated with interferon, and intracellular virus-specific RNA was studied by hybridization with complementary DNA. The steady-state concentration of virusspecific RNA in interferon-treated cells was somewhat greater than that in untreated cells, and the rates of virus-specific RNA synthesis were approximately equal in treated and untreated cells.
Treatment by interferon of mouse cells productively infected with C-type RNA viruses leads to the inhibition of virus production (reviewed by Friedman [9] ). This inhibition is believed to take place at the step of virus assembly and budding, since viral proteins continue to be synthesized in interferon-treated cells (10, 16, 17) , and electron microscopic studies indicate the presence of immature particles at the cell surface (2, 3) . In some systems, virus particles continue to be released from interferon-treated cells at lower levels, but these particles are defective in infectivity (16) . The interferon-sensitive step in viral assembly is a relatively early step, since experiments studying interferontreated cells infected with a temperature-sensitive mutant of Moloney murine leukemia virus (M-MuLV) which is defective at a very late stage of viral assembly indicate that the interferon block occurs before the temperature-sensitive lesion (4) .
The effect of interferon on virus-specific RNA synthesis in cells chronically infected with MuLV has not been studied in great detail, and exination of this would be useful in determining the mode of action of interferon inhibition. This is particularly important, since one possible explanation of interferon action in MuLV-infected cells might be that synthesis of MuLVspecific virions and/or mRNA is inhibited. Synthesis of MuLV-specific proteins (11, 13) , as well as the production of virus particles with low infectivity (12) , continues in cells in which viral RNA synthesis is inhibited by treatment with actinomycin D, similar to the situation observed in interferon-treated cells. Experiments published so far suggest that virus-specific RNA synthesis continues in interferon-treated MuLV producer cells, as measured by release into the tissue culture supernatant ofuridine-labeled material banding at viral density or by the presence of similar particles associated with cells (1, 4, 18) . However, these experiments did not verify that the uridine-labeled material detected was indeed virus-specific RNA, and in some expenments labeling was begun before the complete inhibitory effect of interferon took place. In the experiments described here, virus-specific RNA in interferon-treated and untreated cells was detected by molecular hybridization with complementary DNA (cDNA). Both the steadystate virus-specific RNA content and synthesis rate of virus-specific RNA were measured.
M-MuLV clone 1 cells, a line of NIH-3T3 mouse cells productively infected with MMuLV, were used for these experiments and were grown as described previously (7) . Overnight (16-to 24-h) treatment of the cells with 30 U of mouse interferon per ml resulted in essentially complete inhibition of further virus particle production (Fig. 1) . Production of virus particles from interferon-treated cells could not be detected, as measured by production into the medium of either labeled RNA (Fig. la) (6) . In the figure, the percentage of mal cDNA hybridization is shown as a function of Crt, the product of the RNA concentration and the time of annealing. In this type of analysis, the virus-specific RNA concentration is inversely proportional to the Crt value at which half-maximal annealing is (14) in 10 ml ofgrowth medium was added. After overnight incubation (24 h) at 37C, 100( Ci of [3H]uridine was added to each tissue culture dish, and incubation was continued for an additional day. The tissue culture supernatant was then harvested and clarified of cell debris by centrifugation at 1,250 x g for 10 min. Virus was then deposited by centrifugation for 45 min at 45,000 rpm and 4°C in a Beckman 50 Ti angle rotor and suspended by sonic oscillation in 0.5 ml of 0.01 M NaCI-0.01 M Tris (pH 7.4). The resuspended virus was then layered on a 25 to 55% sucrose gradient in the same buffer and banded isopycnically by centrifugation for 16 h in a Beckman SW50.1 swinging-bucket rotor at 33,000 rpm and 4°C. After centrifugation, the sucrose gradient was fractionated, and radioactivity in each fraction was determined by liquid scintillation counting, using Aquasol scintillation cocktail (New England Nuclear Corp). Data from the two sucrose gradients are superimposed. Symbols: *, supernatant from untreated cells; 0, supernatant from interferon-treated cells. The approximate density (grams per cubic centimeter) of the different gradient fractions, as calculated from the densities of 25 and 55% sucrose, are shown in the inset; the peak of virus radioactivity in the untreated cells bands is at approximately 1.17 The results presented here indicate that virusspecific RNA synthesis continues at approximately normal rates in interferon-treated mouse cells chronically infected with M-MuLV, and this is reflected in an increase in the steady-state amount of virus-specific RNA. Therefore, a direct effect of interferon on the synthesis of virusspecific RNA can be ruled out, and these data support conclusions of others that the primary site of interferon action of MuLV producer cells is at virus assembly.
Although these results indicate that interferon does not inhibit total virus-specific RNA synthesis in infected cells, it is possible that it might affect the processing or modification of virusspecific nuclear RNA. Previous studies indicate that the intracellular pools of virus-specific virion and mRNA's are distinct (13, 15) , and interferon might specifically inhibit virion RNA production. Further investigation of the intracellular virus-specific RNA might elucidate this question. 
